The short version of reconstitution fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-30 and is reviewed periodically as new material appears.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
3D printing is the use of specialized machines, software programs and materials to automate the process of building certain objects. It is having a rapid growth in the prosthesis, medical implants, novel drug formulations and the bioprinting of human tissues and organs. Companies such as Surgical Theater provide new technology that is capable of capturing 3D virtual images of patients' brains to use as practice for operations. 3D printing allows medical companies to produce prototypes to practice before an operation created with artificial tissue. 3D printing technologies are great for bio-medicine because the materials that are used to make allow the fabrication with control over many design features. 3D printing also has the benefits of affordable customization, more efficient designs, and saving more time. 3D printing could be a precise tool in designing pills to house several drugs, because the control over the structure of pills that 3D Printing provides could in theory help make better pills for drugs that have specific release times. The technology allows the pills to transport to the targeted area and degrade safely in the body. As such, pills could be designed more efficiently and conveniently. In the future, doctors might be giving a digital file of printing instructions instead of a prescription for medicine. 3D printing also may have the benefits of affordable customization, more efficient designs, and saving more time.
=== Asthma === The 2007 National Heart, Lung, and Blood Institute (NHLBI) asthma guidelines recommend against the use of non-selective beta blockers in asthmatics, while allowing for the use of cardio selective beta blockers. Cardio selective beta blocker (β1 blockers) can be prescribed at the least possible dose to those with mild to moderate respiratory symptoms. β2-agonists can somewhat mitigate β-blocker-induced bronchospasm where it exerts greater efficacy on reversing selective β-blocker-induced bronchospasm than the nonselective β-blocker-induced worsening asthma and/or COPD.
=== Completed === A single-arm, phase II trial (003-A1) of carfilzomib in patients with relapsed and refractory multiple myeloma showed that single-agent carfilzomib demonstrated a clinical benefit rate of 36% in the 266 patients evaluated and had an overall response rate of 22.9% and median duration of response of 7.8 months. The FDA approval of carfilzomib was based on results of the 003-A1 trial. In a phase II trial (004), carfilzomib had a 53% overall response rate among patients with relapsed and/or refractory multiple myeloma who had not previously received bortezomib. This study also included a bortezomib-treated cohort. Results were reported separately. This study also found prolonged carfilzomib treatment was tolerable, with approximately 22% of patients continuing treatment beyond one year. The 004 trial was a smaller study originally designed to investigate the impact of carfilzomib treatment in relationship to bortezomib treatment in less heavily pretreated (1–3 prior regimens) patients. A phase II trial (005), which assessed the safety, pharmacokinetics, pharmacodynamics and efficacy of carfilzomib, in patients with multiple myeloma and varying degrees of renal impairment, where nearly 50% of patients were refractory to both bortezomib and lenalidomide, demonstrated that pharmacokinetics and safety were not influenced by the degree of baseline renal impairment. Carfilzomib was tolerable and demonstrated efficacy.
The Military Religious Freedom Foundation received more than 200 complaints from 50 military installations, and said that such statements are a violation of the Uniform Code of Military Justice (UCMJ) and reflect Secretary Hegseth's leadership. Multiple members of Congress are requesting an investigation into the DoD over the statements alleged to have been made by several military commanders using biblical references and claiming that the president was anointed by Jesus. The members included Rep. Chrissy Houlahan D-PA, the ranking member of the House Armed Services Subcommittee on Military Personnel. A letter they sent to the military Inspector General stated, "If accurate, these outrageous statements—justifying a war based on interpretations of biblical prophecies, and informing troops that they are risking their lives to advance a specific religious vision—raises not only glaring Constitutional concerns, but potential violations of Department of Defense regulations regarding religious neutrality and breaches of professional obligations and standards expected of military leadership." The complaint asks to determine: if military commanders made the statements and if so, where did statements first originate in the chain of command; did the statements violate DoD Instruction 1300.17 on religious freedom; how widespread were the comments within the military; did service members fear retaliation for reporting the comments; what guidance and training exists to ensure compliance with the DoD policy; and what action should be taken against personnel who violated the policy.
== History == 2008 – Mesynthes Limited (Wellington, New Zealand) was founded by Brian Ward. 2008 – First patent of ovine forestomach matrix and reinforced biologics. 2009 – Endoform Natural™ cleared by the US FDA for treatment of acute and chronic wounds. 2010 – OFM first described in the scientific literature. 2010 – OFM reinforced biologics first described in scientific literature. 2011 – Partnership with Hollister Wound Care (Libertyville, IL) to launch and commercialize Endoform Natural™. 2012 – Partnership with Tela Bio Inc. to commercialize reinforced biologics. 2013 – OFM reinforced biologics (Ovitex®) cleared by US FDA for hernia repair. 2014 – Corporate headquarters relocated from Wellington New Zealand to Auckland New Zealand. 2015 – Company rebrands to Aroa Biosurgery Limited. 2016 – Ovitex® launched in USA in partnership with Tela Bio Inc (Malvern, PA). 2017 – Endoform Antimicrobial™ cleared by the US FDA. 2017 – Myriad Matrix™ cleared by the US FDA. 2018 – Endoform Antimicrobial™ launched in USA. 2018 – Aroa Biosurgery establishes a joint venture with Hydrofera LLC (Manchester, CT) to sell products for wound care and plastics and reconstructive surgery. 2018 – Aroa Biosurgery opens first US office (San Diego, California). 2019 – Myriad Matrix™ launched in USA for plastic and reconstructive surgery. 2020 – Symphony™ cleared by US FDA. 2020 – Aroa Biosurgery lists on the Australian Securities Exchange. 2021 – Joint venture with Hydrofera LLC dissolved and Aroa's direct sales expanded. 2021 – Myriad Morcells™ cleared by US FDA.
Sources: en.wikipedia.org
Further shell closures beyond the main island of stability in the vicinity of Z = 112–114 may give rise to additional islands of stability. Although predictions for the location of the next magic numbers vary considerably, two significant islands are thought to exist around heavier doubly magic nuclei; the first near 354126 (with 228 neutrons) and the second near 472164 or 482164 (with 308 or 318 neutrons). Nuclides within these two islands of stability might be especially resistant to spontaneous fission and have alpha decay half-lives measurable in years, thus having comparable stability to elements in the vicinity of flerovium. Other regions of relative stability may also appear with weaker proton shell closures in beta-stable nuclides; such possibilities include regions near 342126 and 462154. Substantially greater electromagnetic repulsion between protons in such heavy nuclei may greatly reduce their stability, and possibly restrict their existence to localized islands in the vicinity of shell effects. This may have the consequence of isolating these islands from the main chart of nuclides, as intermediate nuclides and perhaps elements in a "sea of instability" would rapidly undergo fission and essentially be nonexistent. It is also possible that beyond a region of relative stability around element 126, heavier nuclei would lie beyond a fission threshold given by the liquid drop model and thus undergo fission with very short lifetimes, rendering them essentially nonexistent even in the vicinity of greater magic numbers.
== Research == Some of Brayden's research has centered on advanced drug delivery systems and strategies to improve the delivery of macromolecules. He has conducted research on poor intestinal permeability of macromolecules, degradation of peptides in the gastrointestinal tract, and the effects of reduced oral bioavailability on therapeutic effectiveness. His studies have investigated intestinal permeation enhancers to promote peptide absorption, technologies aimed at enhancing intestinal absorption, and methods to reduce the need for injectable drug administration. Another strand of Brayden's work has explored methods such as pH-sensitive encapsulation for delivering macromolecules directly to intestinal regions. These approaches included formulation-based strategies to improve mucosal transport of therapeutic peptides, enabling controlled and site-specific drug release. He has also contributed to translational and interdisciplinary research in drug delivery technologies. He worked on oral peptide drug delivery using silica-based nanotechnology systems and explored biomaterial-based nanocomplexes for drug delivery applications. He documented that intra-articular nanocomplexes entrapping selected molecules reduce inflammation by modulating inflammatory gene expression. His research has also focused on the development of oral formulations of peptide-based therapies as alternatives to injectable administration.
When the IBD column compared to recently established PNIPAAm columns, electrostatic forces show remarkably higher retention ability of charged compounds than its hydrophilic predecessor. A single stationary phase can accomplish pharmaceutical separations based on hydrophobic interactions, hydrophilic interactions, and electrostatic interactions merely by adjusting the temperature (while adjusting pH to tweak the LCST).
=== Legal basis in Austria === The legal basis for radiation protection in Austria is the Radiation Protection Act (BGBl. 277/69 as amended) of June 11, 1969. The tasks of radiation protection extend to the fields of medicine, commerce and industry, research, schools, worker protection and food. The General Radiation Protection Ordinance, Federal Law Gazette II No. 191/2006, has been in force since June 1, 2006. Based on the Radiation Protection Act, it regulates the handling of radiation sources and measures for protection against ionizing radiation. The Optical Radiation Ordinance (VOPST) is a detailed ordinance to the Occupational Safety and Health Act (ASchG). On August 1, 2020, a new radiation protection law came into force, which largely harmonized the radiation protection regulations for artificial radioactive substances and terrestrial natural radioactive substances. They are now enshrined in the General Radiation Protection Ordinance 2020. Companies that carry out activities with naturally occurring radioactive substances are now subject to the licensing or notification requirements pursuant to Sections 15 to 17 of the Radiation Protection Act 2020, unless an exemption provision pursuant to Sections 7 or 8 of the General Radiation Protection Ordinance 2020 applies. Cement production including maintenance of clinker kilns, production of primary iron and tin, lead and copper smelting are included in the scope. If a company falls within the scope of the General Radiation Protection Ordinance 2020, its owner must commission an officially authorized monitoring body.
=== Single-Crystal X-ray Diffraction === Single-crystal X-ray diffraction serves as the definitive method for determining atomic-level structure of organic cages. This technique provides precise information about spatial arrangements of atoms, revealing exact bond lengths, angles, and the three-dimensional architecture of the cage framework. Critical structural features such as cavity dimensions, shape, and packing arrangements in the solid state can be determined with high accuracy.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.